OBI Pharma, Inc. (OBI), a global clinical-stage oncology company focused on developing novel cancer therapies such as antibody-drug conjugates (ADCs) and active immunotherapies (4174. TWO), and GlyTech, Inc. (GlyTech), a Japanese manufacturer specializing in glycan production and chemical glycosylation technologies, have entered into a commercialization agreement and a material transfer agreement.

Under the terms of the commercialization agreement, OBI grants GlyTech the rights to commercialize and promote OBI’s GlycOBI® ADC enabling technologies, powered by EndoSymeOBI®, to potential pharmaceutical and biotech partners in Japan. GlyTech will also be a key supplier of glycans in Japan. Under the terms of the material transfer agreement, OBI will transfer certain of its advanced materials to GlyTech for research to advance the efficient production of glycans for ADCs.

Heidi Wang, Ph.D., Managing Director of OBI Pharma, said, “GlyTech is one of our trusted suppliers for high-quality glycans. We are excited to collaborate with GlyTech to expand the reach of OBI’s novel GlycOBI® ADC enabling technologies to potential pharmaceutical and biotech partners in Japan. We also look forward to collaborative research with GlyTech, which is part of our plan to ensure scalable, high-quality glycan manufacturing and supply for ADCs.”

Hiroaki Asai, Chairman and CEO of GlyTech, added: “OBI Pharma’s innovative GlycOBI® ADC technologies are a testament to their mastery of enzyme-based precision synthetic organic chemistry. GlyTech, Inc. is pleased to support the contribution of GlycOBI® ADC technologies to the world as a supplier of highly pure human glycans, a key material for this technology. We look forward to OBI Pharma’s continued progress in developing new drugs.”

 

Source: globenewswire.com

Report Abuse